CTOs on the Move

Invitrogen Corporation

www.invitrogen.com

 
Life Technologies Corp., (NASDAQ: LIFE) www.lifetechnologies.com - On November 21, 2008, Invitrogen Corporation and Applied Biosystems Inc announced the completion of their merger transaction. Effective November 24, 2008, the two companies merged to form a new company under the name, Life Technologies Corporation
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NarrativeDx

NarrativeDx is the artificial intelligence platform for patient experience. Our SaaS platform is the market leader in transforming hospitals` clinical outcomes by extracting data trends and gaining visibility into the patient experience. We help hospital leaders and care providers understand and improve their institution`s patient experience, drive patient referrals, increase hospital revenue, and boost hospital reputations.

Zuchelli

Zuchelli is a Seaford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carstens

For more than 130 years, Carstens has focused on the specific and evolving needs of healthcare professionals - providing revolutionary solutions that transform clinical environments, enhance patient experiences and positively impact results. The first to bring patient information to the point of care, we have always been passionate about connecting with the human side of healthcare. Today, we continue to lead the industry with our inventive product development - bringing new solutions to new demands for more efficient, productive and interactive care. Carstens - connecting with the human side of healthcare.

Marina Care Ctr

Marina Care Ctr is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.